DaVita Raised Guidance. The Market Took 20% Off the Stock. Both Are Right.

DaVita is a $12.3 billion dialysis utility that just told investors three good things in one hour. Integrated Kidney Care will earn at least $65 million this year, $25 million more than promised three months ago. The new expanded HD dialyzer — the one with a plausible 20%-plus mortality benefit — goes national next week, not next year. And the ESRD final rule came in 150 basis points better than the proposed version for large dialysis organizations. The stock, meanwhile, sits 19.8% below its July 29 peak of $240.96, down 9.3% over the last 90 trading days, despite being up more than 58% year-to-date as recently as late September. That divergence is the story: DaVita's operating quarter was genuinely good, and its terminal-value debate got worse.

The dialyzer that costs now and pays later

Strip the enthusiasm out of Javier Rodriguez's opening and you find an unusually clean piece of capital allocation. The company piloted expanded HD across 150 centers and more than 10,000 patients, found over 90% adoption among clinically eligible patients — against an eligible pool of roughly 75% of census — and trained over 95% of clinical teammates. The dialyzers are compatible with existing machines, so there is no capex cliff. And then the sentence that matters:

This is not new — Joel Ackerman said essentially the same thing in August: “The impact is insignificant until the mortality benefit kicks in... We wouldn't expect the positive mortality impact to start until 2028.” — Joel Ackerman, Chief Financial Officer · 2026-08-04 What is new is the certainty of execution. The rollout is no longer a plan, it is a November calendar item. Investors are being asked to underwrite a 2028 volume inflection on an asset with a five-to-seven year average patient life, which is precisely the kind of duration risk that gets marked down when policy risk rises. Note also Kevin Fischbeck's probe — is the mortality benefit just adding Medicare years? Ackerman's answer is genuinely unresolved: “The early results are that is not the pure dynamic, that there are younger patients earlier in their journey whose lives are being extended.” — Joel Ackerman, Chief Financial Officer and Treasurer · 2026-10-29 If that holds, it is volume growth at commercial-ish mix. If not, it is 100% Medicare treatments. Nobody knows yet, and the call was honest about it.

IKC: management's own sandbag, removed

Here is the sharpest contrast in the transcript. In February, Pito Chickering asked why the improvement in IKC couldn't continue at prior rates. Ackerman: “I think it's just a natural occurrence as the business matures and gets bigger, there's just less opportunity to continue to drive the margins up... I think $20 million a year is a comfortable landing spot for us right now in terms of contribution to OI growth.” — Joel Ackerman, Chief Financial Officer (CFO) · 2026-02-02 Six months later, IKC is guiding to a $45 million year-over-year improvement, driven by a higher shared savings rate in the CKCC Medicare fee-for-service demonstration and MA value-based contracts, plus a new Humana CKD program covering roughly 10,000 patients. Rodriguez was explicit that this is now a growth business, not just a maturation story: “our confidence and our capabilities in both the clinical and actuarial has now reached a point that we want to pursue more business.” — Javier Rodriguez, Chief Executive Officer · 2026-10-29 The market may be discounting that because IKC revenue recognition has been lumpy for years — Q2 2025's pull-forward, the plan-year reconciliation timing — and because Ackerman refuses to size 2027. Fair. But the direction of the surprise has flipped from negative to positive.

The 3.5% that isn't 3.5%, and the plan that isn't a plan

On the rate update, Ackerman did the most valuable thing a CFO can do — he defused a headline. The 3.5% LDO rate increase only holds for Q1 because TDAPA add-on payments, now dominated by DefenCath, are recalculated quarterly. Only 40 basis points is fixed for the year. Net 2027 impact, his estimate: 1.5%-2%, or roughly $45-60 million given that a 1% Medicare move is worth about $30 million. That is a real raise over the proposal, but nowhere near what the print suggests.

Then there is the HHS Kidney Care National Plan, which produced the call's only flash of genuine anger. Rodriguez defended scale and the cross-subsidy with a candor you rarely get on these calls:

90% of patients are covered by the government insurance with roughly 1% Medicare increase for the past decade. There's an assumption in there that the cross-subsidy by the private insurance and the one in 10 is accepted by the model... the limited competition is not due to how we operate, but rather how hard it is to take care of this vulnerable population with high needs at 90% government mix.

He also pre-emptively defended the American Kidney Fund's charitable premium assistance mechanism, noting the grants have survived investigations and rulemaking and that most commercial patients do not use it. That is the real tail risk: the Kidney Care National Plan targets exactly the private insurance cross-subsidy that funds roughly a tenth of the revenue base at inflated rates. Rodriguez's own framing — that diluting it would push more patients onto government payers — is economically correct and politically ineffective.

What quietly stopped being a story

Phosphate binder reimbursement was DaVita's number-one keyword theme two quarters ago. This quarter it barely registers — because the final rule permanently incorporated binders into the bundle and binder costs actually declined year-over-year. A resolved uncertainty is the most bullish thing in the deck, and it explains why the guidance narrowing was driven by higher technology spend, not by reimbursement fear. Likewise capacity utilization lingered at the bottom of the keyword list: still in the high 50s versus roughly 65% pre-COVID, still no clinic closures planned. That is several hundred million dollars of latent operating leverage nobody is paying for.

Two things did get vaguer. The 2027 ACA headwind, previously quantified at $70 million, was this quarter reduced to "a headwind from commercial mix, with ACA being the big component." And on costs, “IT spend will not come down next year. Our expectation is it will decelerate.” — Joel Ackerman, Chief Financial Officer and Treasurer · 2026-10-29 After $1 billion of technology investment, the payoff is still on layaway.

The balance sheet is where the humility belongs. effective net cash of -$10.1 billion and liabilities at 93.9% of assets mean this is a rate-sensitive story in a quarter where rising rate environments was a top-75 global market theme. Management hedges ~80% of floating rate debt with three-year caps, which buys time, not immunity. And with operating margin at 16.3% against 33.8% in 2017Q1, the equity is a spread business wearing a growth label. At roughly 9.6x price-to-free-cash-flow, the market has already priced the pessimism. The next twelve months will decide whether the dialyzer is real optionality or a $1 billion science project with a 2028 amortization schedule.